A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs PTT 4256 (Primary)
- Indications Cervical cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Acronyms RAISIC-1
- Sponsors Pathios Therapeutics
- 20 Nov 2024 According to a Pathios Therapeutics media release, the RAISIC-1 trial is being run by the Australian-based team at Pathios Therapeutics Pty Ltd, in partnership with key Australian clinical trial sites and collaborators, contract research organisations and M:M Bio Pty Ltd, part of the global Molecule to Medicine (MTM) ecosystem of companies.
- 20 Nov 2024 According to a Pathios Therapeutics media release, the company announced dosing of the first patient in the initial module of a Phase 1/2 clinical trial evaluating PTT-4256.
- 14 Nov 2024 Status changed from not yet recruiting to recruiting.